These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 9187700)

  • 1. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
    Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
    Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined finasteride and flutamide therapy in men with advanced prostate cancer.
    Ornstein DK; Rao GS; Johnson B; Charlton ET; Andriole GL
    Urology; 1996 Dec; 48(6):901-5. PubMed ID: 8973674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.
    Ornstein DK; Smith DS; Andriole GL
    Urology; 1998 Dec; 52(6):1094-7. PubMed ID: 9836561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
    Tay MH; Kaufman DS; Regan MM; Leibowitz SB; George DJ; Febbo PG; Manola J; Smith MR; Kaplan ID; Kantoff PW; Oh WK
    Ann Oncol; 2004 Jun; 15(6):974-8. PubMed ID: 15151957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
    Barqawi AB; Moul JW; Ziada A; Handel L; Crawford ED
    Urology; 2003 Nov; 62(5):872-6. PubMed ID: 14624911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen for flutamide/finasteride-induced gynecomastia.
    Staiman VR; Lowe FC
    Urology; 1997 Dec; 50(6):929-33. PubMed ID: 9426725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group.
    Kirby R; Robertson C; Turkes A; Griffiths K; Denis LJ; Boyle P; Altwein J; Schröder F
    Prostate; 1999 Jul; 40(2):105-14. PubMed ID: 10386471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results.
    Fleshner NE; Trachtenberg J
    Eur Urol; 1993; 24 Suppl 2():106-12. PubMed ID: 7505229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
    Monk JP; Halabi S; Picus J; Hussain A; Philips G; Kaplan E; Ahles T; Gu L; Vogelzang N; Kelly WK; Small EJ;
    Cancer; 2012 Sep; 118(17):4139-47. PubMed ID: 22180287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
    Fleshner NE; Trachtenberg J
    J Urol; 1995 Nov; 154(5):1642-5; discussion 1645-6. PubMed ID: 7563310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.